Kynurenine, a tryptophan metabolite, exacerbates Alzheimer’s disease (AD) by inhibiting astrocyte glycolysis and lactate production, starving neurons. IDO1 inhibitors, which block kynurenine production, could potentially treat AD and other neurodegenerative diseases.